Atypical C-ANCA following high dose intravenous immunoglobulin

Journal of Clinical Pathology

Volumn 52, Issue 3, 1999, Pages 177-180

  Jolles, Stephen ^a,d   Deacock, Sarah ^a   Turnbull, Wayne ^a   Silvestrini, Roger ^b   Bunn, Chris ^a   White, Peter ^c   Ward, Milford ^c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b WESTMEAD HOSPITAL   (Australia)

^c Department of Immunology ^*  (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Antineutrophil cytoplasmic antibodies; Intravenous immunoglobulin

Indexed keywords

ALPHA GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; STAINING; SUBSTITUTION THERAPY;

EID: 0032980190     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.3.177     Document Type: Article

References (19)

1. 1 Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
2. 2 Jolles S, Hughes JR, Whittaker SJ. Dermatological uses of high dose intravenous immunoglobulin (hdIVIg). Arch Dermatol 1998;134:80-6.
3. 3 Mouthon SV, Kaveri SH, Spalter S, et al. Mechanisms of action of intravenous immune globulin in immune mediated diseases. Clin Exp Immunol 1996;104(suppl 1):3-10.
4. 4 Rutter GH. Requirements for safety and quality of intravenous immunoglobulin G preparations. J Neurol Neurosurg Psychiatry 1994;57(suppl):2-5.
5. 5 Mouthon L, Kazatchkine MD. Autoantibodies in therapeutic preparations of human IgG (IVIg). In: Peter JB, Schoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier Science, 1996:91-6.
6. 6 Roberts DE. Antineutrophil cytoplasmic antibodies. Clin Lab Med 1992;12:85-98.
7. 7 Savage COS, Harper L, Adu D. Primary systemic vasculitis. Lancet 1997;349:553-8.
8. 8 Rasmussen N, Wiik A. Indirect immunofluorescence examination for IgG-ANCA in sera submitted for the 1st international workshop on ANCA, 1988. APMIS 1989; 97(suppl 6):16-20.
9. 9 Lock RJ. ACP Broadsheet No 143: Detection of autoantibodies to neutrophil cytoplasmic antigens. J Clin Pathol 1994;47:4-8.
10. 10 Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS 1989; 97(suppl 6):12-13.
11. 11 Gross WL, Csernok E, Szymkowiak CH. Antineutrophil cytoplasmic antibodies with specificity for proteinase 3. In: Peter JB, Schoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier Science, 1996:61-8.
12. 12 Kallenberg CGM. Antineutrophil cytoplasmic antibodies with specificity for myeloperoxidase. In: Peter JB, Schoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier Science, 1996:53-61.
13. 13 Zhao MH, Lockwood CM. Antineutrophil cytoplasmic antibodies with specificity other than proteinase 3 and myeloperoxidase (X ANCA). In: Peter JB, Schoenfeld Y, eds. Autoantibodies. Amsterdam: Elsevier Science, 1996: 68-74.
14. 14 Jennings JG, Chang L, Savige JA. Anti-proteinase 3 antibodies, their characterization and disease associations. Clin Exp Immunol 1994;95:251-6.
15. 15 Zhao MH, Jones SJ, Lockwood CM. Bactericidal/ permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic antibodies in vasculitis. Clin Exp Immunol 1995;99:49-56.
16. 16 Ayliffe W, Haeney M, Roberts SC, et al. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy [letter]. Lancet 1992;339:558-9.
17. 17 Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin [letter]. N Engl J Med 1992;326:270-1.
18. 18 Lassiter HA, Bibb KW, Bertolone SJ, et al. Neonatal immune neutropenia following the administration of immune globulin. Am J Pediatr Hematol Oncol 1993;15: 120-3.
19. 19 Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996;104(suppl 1):77-83.